Aeglea BioTherapeutics Profit Margin

As of the most recent data (March 2026), AGLE shows a profit margin of -Infinity%. That compares with 95.99% in the prior-year period — down Infinity% year over year. That is below the Healthcare sector average of 15.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AGLE's profit margin is now -Infinity% (was 95.99%) — a Infinity% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Aeglea BioTherapeutics is outperforming or lagging.

The Healthcare sector average profit margin is about 15.58%. Aeglea BioTherapeutics is at -Infinity%, which is lower that average. That is roughly Infinity% below the sector mean. Use the comparison chart on this page to see how AGLE stacks up against individual peers as well.

That compares with 95.99% in the prior-year period — down Infinity% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Aeglea BioTherapeutics with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Aeglea BioTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -Infinity%) with ownership activity and broader fundamentals.